Stephen Dann

Stephen completed his biology Ph.D. at the University of Victoria and then a postdoc on mTOR/S6K signaling with George Thomas at the University of Cincinnati. He then spent over a decade at Pfizer developing small molecule oncology drugs. Most recently, he was the Research Project Leader for the next generation CDK2/4/6 and CDK2-selective inhibitors currently undergoing Phase I clinical testing in hormone receptor positive breast cancer.